Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.
作者信息
Kohrt Holbrook E, Sagiv-Barfi Idit, Rafiq Sarwish, Herman Sarah E M, Butchar Jonathon P, Cheney Carolyn, Zhang Xiaoli, Buggy Joseph J, Muthusamy Natarajan, Levy Ronald, Johnson Amy J, Byrd John C
机构信息
Division of Oncology, Department of Medicine, Stanford University Cancer Institute, Stanford, CA.
出版信息
Blood. 2014 Mar 20;123(12):1957-60. doi: 10.1182/blood-2014-01-547869.
Abstract
摘要
相似文献
1
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.
Blood. 2014 Mar 20;123(12):1957-60. doi: 10.1182/blood-2014-01-547869.
2
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Haematologica. 2015 Jan;100(1):77-86. doi: 10.3324/haematol.2014.107011. Epub 2014 Oct 24.
3
Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib.
Ann Hematol. 2019 Jan;98(1):205-207. doi: 10.1007/s00277-018-3381-y. Epub 2018 May 26.
4
Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.
Leuk Lymphoma. 2017 Mar;58(3):699-707. doi: 10.1080/10428194.2016.1201567. Epub 2016 Aug 9.
5
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
Blood. 2015 Aug 13;126(7):842-50. doi: 10.1182/blood-2014-12-617522. Epub 2015 Jun 26.
6
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Future Oncol. 2015;11(1):51-9. doi: 10.2217/fon.14.119.
7
Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
MAbs. 2014;6(5):1300-13. doi: 10.4161/mabs.32106. Epub 2014 Oct 30.
8
The efficacy of ibrutinib in the treatment of Richter syndrome.
Blood. 2015 Mar 5;125(10):1676-8. doi: 10.1182/blood-2014-12-610782.
9
Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors.
Biomed Res Int. 2018 Mar 19;2018:1023490. doi: 10.1155/2018/1023490. eCollection 2018.
10
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Expert Opin Investig Drugs. 2018 Jan;27(1):31-42. doi: 10.1080/13543784.2018.1404027. Epub 2017 Nov 15.
引用本文的文献
1
Modulation of anti-tumour immunity by XPO1 inhibitors.
Explor Target Antitumor Ther. 2025 Apr 23;6:1002310. doi: 10.37349/etat.2025.1002310. eCollection 2025.
2
Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges.
Front Pharmacol. 2025 Jan 3;15:1517972. doi: 10.3389/fphar.2024.1517972. eCollection 2024.
3
Secondary Hemophagocytic Lymphohistiocytosis Syndrome Developing in a Patient With Chronic Lymphocytic Leukemia Under a Long-term Ibrutinib Therapy: A Case Report and Literature Review.
J Immunother. 2025 Apr 1;48(3):109-112. doi: 10.1097/CJI.0000000000000547. Epub 2024 Dec 27.
4
Sequelae of B-Cell Depleting Therapy: An Immunologist's Perspective.
BioDrugs. 2025 Jan;39(1):103-130. doi: 10.1007/s40259-024-00696-9. Epub 2024 Dec 16.
5
Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en réanimation onco-hématologique (GRRR-OH) study.
Ann Intensive Care. 2023 Dec 6;13(1):123. doi: 10.1186/s13613-023-01219-5.
6
Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies.
Front Cell Dev Biol. 2023 Oct 31;11:1270398. doi: 10.3389/fcell.2023.1270398. eCollection 2023.
7
Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies.
Sci Rep. 2023 Nov 21;13(1):20412. doi: 10.1038/s41598-023-47735-z.
8
Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment.
Biomedicines. 2023 Sep 24;11(10):2621. doi: 10.3390/biomedicines11102621.
9
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.
Leukemia. 2023 Oct;37(10):2036-2049. doi: 10.1038/s41375-023-01984-z. Epub 2023 Aug 1.
10
Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis.
Sci Rep. 2023 Jun 16;13(1):9775. doi: 10.1038/s41598-023-36279-x.
本文引用的文献
1
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Blood. 2013 Oct 10;122(15):2539-49. doi: 10.1182/blood-2013-06-507947. Epub 2013 Jul 25.
2
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19.
3
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
Blood. 2011 Feb 24;117(8):2423-32. doi: 10.1182/blood-2010-08-301945. Epub 2010 Dec 30.
4
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.
Nat Chem Biol. 2011 Jan;7(1):41-50. doi: 10.1038/nchembio.481. Epub 2010 Nov 28.
5
Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk.
J Immunol. 2007 Mar 15;178(6):3575-82. doi: 10.4049/jimmunol.178.6.3575.
6
From the bench to the bedside: ways to improve rituximab efficacy.
Blood. 2004 Nov 1;104(9):2635-42. doi: 10.1182/blood-2004-03-1110. Epub 2004 Jun 29.
Zotero 插件